Table 2

The levels of LDL-C at baseline and follow up in each arm of included trials
Authors Trial name Management in each arm N LDL-C level
At Baseline At Follow-up
Tardif JC A-PLUS Avasimibe50 108 92.8 ± 1.7 100*
Tardif JC A-PLUS Avasimibe250 98 93.4 ± 1.6 101.9*
Tardif JC A-PLUS Avasimibe750 117 91.4 ± 1.6 101.4*
Tardif JC A-PLUS Placebo 109 89.6 ± 1.6 91.1*
Okazaki S ESTABLISH Control 24 123.9 ± 35.3 119.4 ± 24.6
Okazaki S ESTABLISH Atorvastatin 24 124.6 ± 34.5 70.0 ± 25.0
Yokoyama M Control 30 131.5 ± 23# 124.5 ± 24.1#
Yokoyama M Atorvastatin 29 133 ± 13 87 ± 29
Nissen SE REVERSAL Atorvastatin 253 150.2 ± 27.9 78.9 ± 30.2
Nissen SE REVERSAL Pravastatin 249 150.2 ± 25.9 110.4 ± 25.8
Nissen SE ACTIVATE Pactimibe 206 101.4 ± 27.7 91.3
Nissen SE ACTIVATE Placebo 202 101.5 ± 31.1 86.4
Nissen SE ILLUSTRATE Atorvastatin 446 84.3 ± 18.9 87.2 ± 22.6
Nissen SE ILLUSTRATE Atorva+torcetrapib 464 83.1 ± 19.7 70.1 ± 25.4
Kawasaki M Control 17 152 ± 20 149 ± 24
Kawasaki M Pravastatin 18 149 ± 19 102 ± 13
Kawasaki M Atorvastatin 17 155 ± 22 95 ± 15
Hiro T JAPAN-ACS Pitavastatin 125 130.9 ± 33.3 81.1 ± 23.4
Hiro T JAPAN-ACS Atorvastatin 127 133.8 ± 31.4 84.1 ± 27.4
Nissen SE ASTEROID Rosuvastatin 349 130.4 ± 34.3 60.8 ± 20.0
Takayama T COSMOS Rosuvastatin 126 140.2±31.5 82.9±18.7
Lee CW ARTMAP Atorvastatin 143 110 ± 31 56 ± 18
Lee CW ARTMAP Rosuvastatin 128 109 ± 31 53±18
Yamada T REACH Atorvastatin 26 123 ± 17 83 ± 22
Yamada T REACH Control 32 115 ± 14 115 ± 30
Nasu K Fluvastatin 40 144.9 ± 31.5 98.1 ± 12.7
Nasu K Control 39 122.3 ± 18.9 121.0 ± 21.2
Nicholls SJ SATURN Atorvastatin 519 119.9 ± 28.9 70.2 ± 1.0
Nicholls SJ SATURN Rosuvastatin 520 120.0 ± 27.3 62.6 ± 1.0
Hong MK Simvastatin 50 119 ± 30 78 ± 20
Hong MK Rosuvastatin 50 116 ± 28 64 ± 21
Tani S Pravastatin 52 130 ± 38 104 ± 20
Tani S Control 23 123 ± 28 120 ± 30
Rodés-C Bef ERASE Statins before ACS 38 71 ± 23 77 ± 25
Rodés-C Aft ERASE Statins after ACS 36 100 ± 30 63 ± 17
Jensen LO Simvastatin 40 158.7 ± 30.6 85.1 ± 22.1
Nissen SE PERISCOPE Statins+Gli 181 94.4 ± 32.9 96.1 ± 30.4
Nissen SE PERISCOPE Statins+Pio 179 93.5 ± 30.7 95.6 ± 28.9
Nissen SE STRADIVARIUS Statins+Rim 335 91.9 ± 27.9 87.6 ± 30.5
Nissen SE STRADIVARIUS Statins+Con 341 89.5 ± 32.2 86.3 ± 30.3

Note: *calculated on the bases of baseline levels and change percentage at follow up [21].

# calculated according to Figure 2 in the paper [15].

Gao et al.

Gao et al. BMC Cardiovascular Disorders 2014 14:60   doi:10.1186/1471-2261-14-60

Open Data